Sangamo BioSciences to Release First-Quarter 2001 Financial Results On April 25, 2001

Apr 18, 2001, 01:00 ET from Sangamo BioSciences, Inc.

    RICHMOND, Calif., April 18 /PRNewswire/ --
 Sangamo BioSciences, Inc. (Nasdaq:   SGMO) today announced that the company will
 release its first-quarter financial results on Wednesday, April 25, 2001 after
 the market closes.  The earnings release will be followed by a conference call
 at 2:00 p.m. PDT, which will be open to the public.  During the conference
 call, the company will review the results and discuss other business matters.
     The conference call dial-in numbers are 800-730-7991 for domestic callers
 and 706-634-7552 for international callers.  For those unable to listen in at
 the designated time, a conference call replay will be available for 1 week
 following the conference call, from approximately 4:00 p.m. PDT on
 April 25, 2001 to 4:00 p.m. PDT on May 2, 2001.  The conference call replay
 numbers for domestic and international callers are 800-642-1687 and
 706-645-9291 respectively.  The conference ID number for the replay is 657450.
 
     About Sangamo
     Sangamo is focused on the research and development of novel transcription
 factors for the regulation of gene expression. Sangamo's Universal Gene
 Recognition(TM) technology enables the engineering of transcription factors
 known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so
 that they can recognize a specific gene, Sangamo has created ZFP transcription
 factors that can control gene expression, and consequently, cell function. The
 company intends to establish Universal Gene Recognition as a widely used
 technology for commercial applications in pharmaceutical discovery, human
 therapeutics, clinical diagnostics, agriculture and industrial biotechnology.
 Over twenty leading pharmaceutical and biotechnology companies have utilized
 ZFPs. In addition, Sangamo is developing novel ZFP-based therapeutics for the
 treatment of cardiovascular disease. For more information about Sangamo, visit
 the company's web site at www.sangamo.com.
     This press release contains forward-looking information within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934, and is subject to the safe harbors created by those
 sections. Actual results may differ materially from these forward-looking
 statements. See the company's SEC filings, and in particular, the risk factors
 described in the company's Annual Report on Form 10-K and its most recent
 10-Q. Sangamo assumes no obligation to update the forward-looking information
 contained in this press release. Further, Sangamo assumes no obligation to
 update any guidance given on its upcoming conference call.
 
 

SOURCE Sangamo BioSciences, Inc.
    RICHMOND, Calif., April 18 /PRNewswire/ --
 Sangamo BioSciences, Inc. (Nasdaq:   SGMO) today announced that the company will
 release its first-quarter financial results on Wednesday, April 25, 2001 after
 the market closes.  The earnings release will be followed by a conference call
 at 2:00 p.m. PDT, which will be open to the public.  During the conference
 call, the company will review the results and discuss other business matters.
     The conference call dial-in numbers are 800-730-7991 for domestic callers
 and 706-634-7552 for international callers.  For those unable to listen in at
 the designated time, a conference call replay will be available for 1 week
 following the conference call, from approximately 4:00 p.m. PDT on
 April 25, 2001 to 4:00 p.m. PDT on May 2, 2001.  The conference call replay
 numbers for domestic and international callers are 800-642-1687 and
 706-645-9291 respectively.  The conference ID number for the replay is 657450.
 
     About Sangamo
     Sangamo is focused on the research and development of novel transcription
 factors for the regulation of gene expression. Sangamo's Universal Gene
 Recognition(TM) technology enables the engineering of transcription factors
 known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so
 that they can recognize a specific gene, Sangamo has created ZFP transcription
 factors that can control gene expression, and consequently, cell function. The
 company intends to establish Universal Gene Recognition as a widely used
 technology for commercial applications in pharmaceutical discovery, human
 therapeutics, clinical diagnostics, agriculture and industrial biotechnology.
 Over twenty leading pharmaceutical and biotechnology companies have utilized
 ZFPs. In addition, Sangamo is developing novel ZFP-based therapeutics for the
 treatment of cardiovascular disease. For more information about Sangamo, visit
 the company's web site at www.sangamo.com.
     This press release contains forward-looking information within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934, and is subject to the safe harbors created by those
 sections. Actual results may differ materially from these forward-looking
 statements. See the company's SEC filings, and in particular, the risk factors
 described in the company's Annual Report on Form 10-K and its most recent
 10-Q. Sangamo assumes no obligation to update the forward-looking information
 contained in this press release. Further, Sangamo assumes no obligation to
 update any guidance given on its upcoming conference call.
 
 SOURCE  Sangamo BioSciences, Inc.